Evidence map›Paper›PMID 34698239›Full record

ReviewMedical sciences (Basel, Switzerland)2021

Early Gestational Diabetes Mellitus: Diagnostic Strategies and Clinical Implications.

Saptarshi Bhattacharya, Lakshmi Nagendra, Aishwarya Krishnamurthy, Om J Lakhani, Nitin Kapoor, Bharti Kalra, Sanjay Kalra

Open access · goldAbstract readReview
In one paragraph

Review in Medical sciences (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. The AACE 2022 Guideline: An Academic Appraisal.TouchREVIEWS in endocrinology · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Saptarshi BhattacharyaDepartment of Endocrinology, Max Hospital, New Delhi 110092, India.ORCID 0000-0002-8458-9371
Lakshmi NagendraDepartment of Endocrinology, K.S Hegde Medical Academy, Mangalore 575018, India.
Aishwarya KrishnamurthyDepartment of Endocrinology, Max Hospital, Ghaziabad 201012, India.
Om J LakhaniDepartment of Endocrinology, Zydus Hospital, Ahmedabad 380058, India.
Nitin KapoorDepartment of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore 632004, India.ORCID 0000-0002-9520-2072
Bharti KalraDepartment of Obstetrics, Bharti Hospital, Karnal 132001, India.
Sanjay KalraDepartment of Endocrinology, Bharti Hospital, Karnal 132001, India.
Bharti Hospital · INMax Healthcare · INCadila Healthcare (India) · INChristian Medical College, Vellore · INK S Hegde Medical Academy · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preexisting diabetes mellitus (DM) should be ruled out early in pregnancy in those at risk. During screening, a significant proportion of women do not reach the threshold for overt DM but fulfill the criteria used for diagnosing conventional gestational DM (cGDM). There is no consensus on the management of pregnancies with intermediate levels of hyperglycemia thus diagnosed. We have used the term early gestational DM (eGDM) for this condition and reviewed the currently available literature. Fasting plasma glucose (FPG), oral glucose tolerance test, and glycated hemoglobin (HbA1c) are the commonly employed screening tools in early pregnancy. Observational studies suggest that early pregnancy FPG and Hba1c correlate with the risk of cGDM and adverse perinatal outcomes. However, specific cut-offs, including those proposed by the International Association of the Diabetes and Pregnancy Study Group, do not reliably predict the development of cGDM. Emerging data, though indicate that FPG ≥ 92 mg/dL (5.1 mmol/L), even in the absence of cGDM, signals the risk for perinatal complication. Elevated HbA1c, especially a level ≥ 5.9%, also correlates with the risk of cGDM and worsened outcome. HbA1c as a diagnostic test is however besieged with the usual caveats that occur in pregnancy. The studies that explored the effects of intervention present conflicting results, including a possibility of fetal malnutrition and small-for-date baby in the early treatment group. Diagnostic thresholds and glycemic targets in eGDM may differ, and large multicenter randomized controlled trials are necessary to define the appropriate strategy.

Indexed as

Blood GlucoseDiabetes, GestationalFastingFemaleGlucose Tolerance TestGlycated HemoglobinHumansMulticenter Studies as TopicPregnancyBlood GlucoseGlycated Hemoglobinearly diagnosisearly treatmentfasting hyperglycemiagestational diabetes mellituslarge-for-date babyoral glucose tolerance test

Identifiers

PMID34698239
PMCPMC8544345
OpenAlexW3201603269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.